XML 41 R29.htm IDEA: XBRL DOCUMENT v3.25.2
Revenue (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Disaggregation of Revenue [Line Items]        
Revenues $ 622,849 $ 89,565 $ 716,713 $ 7,706,738
Royalty income, nonoperating 122,849 89,565 216,713 206,738
Verity License Agreement [Member]        
Disaggregation of Revenue [Line Items]        
Royalty income, nonoperating 123,000 $ 90,000 217,000 140,000
License [Member]        
Disaggregation of Revenue [Line Items]        
Revenues $ 500,000   $ 500,000  
License [Member] | Antares Pharma [Member]        
Disaggregation of Revenue [Line Items]        
Revenues       67,000
License [Member] | Verity License Agreement [Member]        
Disaggregation of Revenue [Line Items]        
Revenues       $ 7,500,000
Major Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]        
Disaggregation of Revenue [Line Items]        
Concentration risk, percentage     10.00%  
One Major Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]        
Disaggregation of Revenue [Line Items]        
Concentration risk, percentage 80.00% 100.00% 70.00% 99.00%
Two Major Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]        
Disaggregation of Revenue [Line Items]        
Concentration risk, percentage 20.00%   30.00%